Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

Furie, Richard; H. Rovin, Brad; Garg, Jay; B. Santiago, Mittermayer; Aroca, Gustavo; Elizabeth Zuta Santillán, Adolfina; Álvarez, Dámaris; Navarro Sandoval, Cleyber; Lila, Alexander; A. Tumlin, James; Saxena, Amit; Irazoque Palazuelos, Fedra; Raghu, Harini; Yoo, Bongin; Hassan, Imran; Martins, Elsa; Sehgal, Himanshi; Kirchner, Petra; Ross Terrés, Jorge; A. Omachi, Theodore; H. Schindler, Thomas; F. Pendergraft, William; Malvar, Ana

doi:10.1056/nejmoa2410965

Public

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

Published in New England Journal of Medicine • Feb 7, 2025

Authors:

Richard Furie

Brad H. Rovin

Jay Garg

Abstract

BACKGROUND: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy. METHODS: In a phase 3, randomized, controlled trial, we assigned adults with ...

Subject

Obinutuzumab

Lupus nephritis

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!